Takhzyro denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for takhzyro are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Takhzyro as Non-Formulary — and How to Get a Formulary Exception

A non-formulary denial for Takhzyro (lanadelumab) means it is either excluded from your specific UHC plan's drug list or placed at a tier that requires prior authorization or is not covered without an exception. This is a plan-design decision, not a clinical one — but federal and plan-level rules give you a clear pathway to override it when medically necessary.

Formulary exceptions are a standard, legitimate process. Plans must grant an exception when a non-formulary drug is medically necessary and no formulary alternative is clinically appropriate for you.

## Federal Appeal Rights

• ACA §2719 / ERISA §503 guarantee the right to appeal a formulary exclusion denial.
• Formulary exception request is typically the first step — this is separate from (and faster than) a formal appeal.
• If the exception is denied, file a formal internal appeal within 180 days of the denial notice.
• External review is available approximately 4 months after final internal denial.
• Expedited review is available given the life-threatening potential of uncontrolled HAE.

## Appeal / Exception Timeline

1. Request a formulary exception immediately — submit with prescriber documentation (often resolved in 72 hours or less). 2. If denied, file a formal internal appeal with a complete documentation package. 3. UHC must respond to standard appeals within 30 days; expedited within 72 hours. 4. If the internal appeal is denied, proceed to external IRO review.

## Documentation to Gather

• Diagnosis confirmation: Lab or genetic confirmation of HAE.
• Formulary alternative evaluation: A letter from your prescriber reviewing each formulary HAE agent, if any, and explaining — based on your specific clinical situation — why each is not therapeutically equivalent or appropriate for you.
• Prior treatment history: Dates and outcomes of any HAE therapies you have already tried, including any formulary agents that were tried and failed or are contraindicated.
• Clinical severity: Attack frequency, severity, and risk documentation supporting ongoing prophylactic need.
• Prescriber medical-necessity letter: Statement that Takhzyro is the medically necessary choice for your specific clinical situation, including why formulary alternatives are not clinically interchangeable.

## Criteria-Mapping Structure

Obtain UHC's formulary exception criteria from your plan documents or member services. Map each requirement:

| Exception Requirement | Documentation Response | |---|---| | Non-formulary drug is medically necessary | Prescriber letter with clinical rationale | | Formulary alternatives are inappropriate | Prescriber evaluation of each formulary alternative | | HAE diagnosis confirmed | Lab/genetic report |

Also review your plan's Summary of Benefits and Coverage and Evidence of Coverage document for the formulary exception process. Cross-check the FDA label from DailyMed to confirm Takhzyro's approved indication matches your diagnosis exactly as coded on the claim.